Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06152237 · ClinicalTrials.gov registry record · Phase 1

Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)

A Phase 1 study of Rett Syndrome, sponsored by Taysha Gene Therapies.

Active
Registry status
Phase 1
Development phase
6
Enrollment target
5
Study locations

NCT06152237 is a Phase 1 study of Rett Syndrome that is active but no longer recruiting, run by Taysha Gene Therapies. The registered enrollment target is 6 participants, below the 526-participant average among 18 other Rett Syndrome trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06152237, a Phase 1 study of Rett Syndrome, is active but no longer recruiting, sponsored by Taysha Gene Therapies.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
6 participants
Enrollment target
5
Study locations

Study Summary

The REVEAL Pediatric Study is a multi-center, Phase 1/2 open-label, dose-escalation and dose-expansion study of TSHA-102, an investigational gene therapy, in pediatric females with Rett Syndrome. The safety, tolerability, and preliminary efficacy of two dose levels will be evaluated. The study duration is up to 6 years.

Conditions Studied

Rett Syndrome

Interventions

  • GENETIC TSHA-102

Study Locations (5)

Illinois

  • Rush University Medical Center & Children's Hospital - Chicago

Minnesota

  • Gillette Children's Specialty Healthcare - Saint Paul

Missouri

  • Washington University, St. Louis - St Louis

Quebec

  • CHU Ste-Justine - Montreal

Other

  • Children's Neurosciences, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust - London

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2023-12-12
Est. Completion 2031-11-02
Phase Phase 1

Sponsor

Taysha Gene Therapies

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06152237

The ClinicalTrials.gov registry entry for NCT06152237 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 526-participant average among 18 other Rett Syndrome trials with a reported enrollment target (99% lower). The listed sponsor is Taysha Gene Therapies, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rett Syndrome appearing as the primary indexed condition, and to 1 intervention - of which TSHA-102 is the first listed.

NCT06152237 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Illinois, Minnesota, Missouri.

Frequently Asked Questions

What is clinical trial NCT06152237 about?

NCT06152237 is a clinical study titled "Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)". The REVEAL Pediatric Study is a multi-center, Phase 1/2 open-label, dose-escalation and dose-expansion study of TSHA-102, an investigational gene therapy, in pediatric females with Rett Syndrome. The safety, tolerability, and preliminary efficacy of two dose levels will be evaluated. The study dura...

What is the current status of trial NCT06152237?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2023-12-12. Estimated completion is 2031-11-02.

What conditions does trial NCT06152237 study?

This clinical trial studies the following conditions: Rett Syndrome.

What interventions are being tested in trial NCT06152237?

The interventions under investigation include: TSHA-102 (GENETIC).

Who is sponsoring clinical trial NCT06152237?

This trial is sponsored by Taysha Gene Therapies, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06152237 being conducted?

This trial has 5 study locations across Illinois, Minnesota, Missouri, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rett Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rett Syndrome

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.